Sputum interleukin‐6 level as a marker of severity during acute chest syndrome in children with sickle cell disease

Lara Mayrand,Juliette Elie,Yael Pinhas,Rachel Rignault‐Bricard,Melissa Taylor,Joséphine Brice,Mariane de Montalembert,Claire Heilbronner,Agathe Beranger,Sofia Angyalosy,Stephanie Chhun,Thiago Trovati Maciel,Olivier Hermine,Slimane Allali
DOI: https://doi.org/10.1111/bjh.19561
2024-05-25
British Journal of Haematology
Abstract:Summary Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin‐6 (IL‐6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL‐6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non‐invasive) length ≥5 days, bilateral and/or extensive opacities on chest X‐ray or erythrocytapheresis requirement. Sputum IL‐6 could serve as an ACS severity marker to help identify patients requiring targeted anti‐inflammatory treatments such as tocilizumab.
hematology
What problem does this paper attempt to address?